Literature DB >> 626444

Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study.

K A Huston, G G Hunder, J T Lie, R H Kennedy, L R Elveback.   

Abstract

Among the population of Olmsted County, Minnesota, 42 patients with temporal arteritis were identified during a 25-year period. The average annual incidence per 100 000 population aged 50 and older rose from 5.1 in 1950-1959 to 17.4 in 1970-1974. The prevalence of patients with a history of the diagnosis of temporal arteritis on 1 January 1975 was 133 per 100 000 population aged 50 and older. All patients received corticosteroid therapy for a range of 1 to 77 months (median, 7 months). Relapses in 10 of 11 patients were associated with corticosteroid reduction. The majority of patients recovered fully and were followed off corticosteroids for 10 months to 19 years (median, 5 years). Temporal arteritis had no significant effect on survival. Vertebral compression fractures and myopathy were the most serious complications of therapy. The presence of giant cells in biopsies was in part related to the number of sections examined, and their presence had no apparent influence on the clinical course.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 626444     DOI: 10.7326/0003-4819-88-2-162

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  68 in total

1.  Giant Cell Arteritis.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-06

Review 2.  Angiographic characteristics of Takayasu arteritis.

Authors:  Y D Cho; K T Lee
Journal:  Heart Vessels Suppl       Date:  1992

Review 3.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

Review 4.  Giant cell arteritis presenting as limb claudication.

Authors:  R A Watts; M Coppen; A K Bhalla; A I Binder
Journal:  J R Soc Med       Date:  1989-01       Impact factor: 5.344

Review 5.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 6.  Giant cell arteritis.

Authors:  Todd J Schwedt; David W Dodick; Richard J Caselli
Journal:  Curr Pain Headache Rep       Date:  2006-12

7.  Plasma viscosity or erythrocyte sedimentation rate in the diagnosis of giant cell arteritis?

Authors:  G P Brittain; G G McIlwaine; J A Bell; J M Gibson
Journal:  Br J Ophthalmol       Date:  1991-11       Impact factor: 4.638

8.  Ophthalmic presentation of giant cell arteritis in African-Americans.

Authors:  S T Garrity; M Pistilli; M S Vaphiades; N Q Richards; P S Subramanian; P R Rosa; B L Lam; B J Osborne; G T Liu; K E Duncan; R K Shin; N J Volpe; K S Shindler; M S Lee; M L Moster; E H Tracey; S E Cuprill-Nilson; M A Tamhankar
Journal:  Eye (Lond)       Date:  2016-09-16       Impact factor: 3.775

Review 9.  Giant cell arteritis. Epidemiology and treatment.

Authors:  E Nordborg; R Andersson; B A Bengtsson
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

10.  Anterior ischemic optic neuropathy due to giant cell arteritis with normal inflammatory markers.

Authors:  Efdal Yoeruek; Peter Szurman; Olcay Tatar; Petra Weckerle; Helmut Wilhelm
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-02       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.